Thursday, November 18, 2021 11:09:01 AM
MARK THIS POST and revisit it on 11/15/22. Here's the board's take on where AMRN share price will be that day:
Share price
Avg 20.57
Median 18.44
invest2992 66.00
noelan_s09 43.00
Retiredceo 41.00
Number sleven 35.00
north40000 35.00
Monk44 30.00
Whaler58 29.00
Martinko 28.00
bidmark 27.99
cloudera 26.00
Downtownguy 26.00
BobWayne 25.00
MA52TA 24.00
G550driver 24.00
lizzy241 23.00
ilovetech 23.00
grbnitz4002 22.89
Triple88 18.88
xblkbk 18.00
rafunrafun 17.00
CaptBeer 16.66
alm2 15.00
mag6898 15.00
MNBioMike 12.00
Invest83838 12.00
rosemountbomber 12.00
Scallops 11.50
Notademoc 10.00
Examiner77 9.30
biofalcon 8.75
ralphey 7.40
dogn 6.55
dukesking 6.25
mrmainstreet 6.20
shadolane 5.00
Jvee 3.98
I'll update this if we get more guesses, clearly the numbers started to climb once the discussions heated up on the new activist investor.
Share price
Avg 20.57
Median 18.44
invest2992 66.00
noelan_s09 43.00
Retiredceo 41.00
Number sleven 35.00
north40000 35.00
Monk44 30.00
Whaler58 29.00
Martinko 28.00
bidmark 27.99
cloudera 26.00
Downtownguy 26.00
BobWayne 25.00
MA52TA 24.00
G550driver 24.00
lizzy241 23.00
ilovetech 23.00
grbnitz4002 22.89
Triple88 18.88
xblkbk 18.00
rafunrafun 17.00
CaptBeer 16.66
alm2 15.00
mag6898 15.00
MNBioMike 12.00
Invest83838 12.00
rosemountbomber 12.00
Scallops 11.50
Notademoc 10.00
Examiner77 9.30
biofalcon 8.75
ralphey 7.40
dogn 6.55
dukesking 6.25
mrmainstreet 6.20
shadolane 5.00
Jvee 3.98
I'll update this if we get more guesses, clearly the numbers started to climb once the discussions heated up on the new activist investor.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
